[Proliferation inhibiting and apoptosis inducing effects of parthenolide on human multiple myeloma cells]. 2006

Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

OBJECTIVE To investigate the effect of parthenolide (PTL) on human multiple myeloma (MM) cells in vitro and its mechanism. METHODS Human MM cells of the line PRMI8266 were cultured and treated with PTL of the concentrations of 1, 2.5, 5, 7.5, and 10 micromol/L for 24, 48, or 72 hours. MM cells treated with DMSO were used as control group. The optical density was measured so as to draw a growth curve. The cell viability was detected by MTT and trypan-blue exclusion. The apoptosis was detected by flow cytometry. AO/EB staining and Wright-Giemsa staining were used to observe the morphological changes of the cells by fluorescence microscope and light microscope respectively. The caspase-3 activity was evaluated by BD ApoAlert Caspase Colorimetric Assay Kit. RESULTS PTL significantly inhibited the proliferation and viability of the MM cells time and dose-dependently (all P < 0.01), and significantly induced the cell apoptosis after 48 h in a dose-dependent manner (P < 0.01). The early cell apoptosis rates for PTL of the concentrations of 2, 5 and 10 micromol/L were 17.1% +/- 2.6%, 33.6% +/- 3.8%, and 40.9% +/- 3.1% respectively, all significantly higher than that of the control group (5.6% +/- 1.2%, all P < 0.01). The MM cells treated with PTL of the concentration of 5 micromol/L for 48 h showed typical cell apoptotic features. The caspase-3 activity of the MM cells was enhanced significantly by PTL in a time and dose-dependent manner (all P < 0.01). CONCLUSIONS This first report of anti-proliferation and apoptosis induction effects of PTL on MM cells shows that able to significantly inhibit the proliferation and induce the apoptosis of MM cells and enhance the caspase-3 activity, PTL may be a potentially useful drug for treatment of MM.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000183 Actihaemyl An extract from calf blood containing inorganic salts, amino acids, polypeptides and purines, but no proteins nor antigenic substances or blood group characteristics. Its exact composition is unknown. It has been proposed as a radiation-protective agent. Solcoseryl,S 1021
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D053148 Caspase 3 A short pro-domain caspase that plays an effector role in APOPTOSIS. It is activated by INITIATOR CASPASES such as CASPASE 9. Isoforms of this protein exist due to multiple alternative splicing of its MESSENGER RNA. CASP3,Apopain,Caspase-3,Pro-Caspase-3,Procaspase-3,Pro Caspase 3,Procaspase 3

Related Publications

Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
October 2006, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
October 2020, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
May 2003, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
October 2018, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
August 2017, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
August 2016, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
April 2019, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
November 2009, International journal of hematology,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
December 2012, Zhongguo shi yan xue ye xue za zhi,
Zhi-chao Chen, and Qiu-bai Li, and Jing Shao, and Jian Lü, and Yong You, and Zhao-dong Zhong, and Ping Zou
June 2018, Zhongguo shi yan xue ye xue za zhi,
Copied contents to your clipboard!